| 翻訳と辞書 |
Ibalizumab
Ibalizumab (TMB-355〔(【引用サイトリンク】title=Ibalizumab (TMB-355) )〕 previously known as TNX-355) is a non-immunosuppressive monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits the viral entry process. It is being investigated as an HIV entry inhibitor〔(【引用サイトリンク】title=TNX-355 fact sheet )〕 with the ability to block both CCR5- and CXCR4-tropic viruses,〔 and is undergoing a Phase II clinical trial with an estimated study completion date in December 2010.〔(【引用サイトリンク】title=Dose-Response Study of Ibalizumab + OBR in Patients With HIV-1 )〕 Specific Research is also conducted at the Aaron Diamond AIDS Research Center under the direction of David Ho.〔(【引用サイトリンク】url=http://www.clinicaltrials.gov/ct2/show/NCT01292174 )〕
Results from a previous Phase II of ibalizumab, reported by the original developer Tanox in 2006,〔(【引用サイトリンク】 title=Tanox Reports 48-Week Results From TNX-355 Phase 2 Clinical Trial )〕 showed that persons with HIV who received the drug, in combination with an optimized background regimen (OBR), maintained a considerably greater reduction in viral load and experienced a statistically significant increase in CD4+ cells than did patients given placebo in combination with OBR. Thus, pending results of further trials, it is one of a limited number of viable alternative strategies to contain the virus without recourse to antiretroviral drug cocktails or a vaccine.
== Development ==
Ibalizumab is being developed by TaiMed Biologics but was first developed by Tanox, now part of Genentech. As part of Genentech's takeover of Tanox, the patent for ibalizumab was sold to TaiMed Biologics, a biotech company formed in 2007 with support from the Taiwanese Government through a $20 million investment by the state-owned National Development Fund.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Ibalizumab」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|